Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 794 in Claudin 6-positive solid tumors
NCT05317078Phase 1Terminated
- Sponsor
- Amgen
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of AMG 794 in non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), testicular germ cell cancer (TGCC) and 2 more (2 cohorts), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity at 28 days, Treatment-emergent Adverse Event at 2 years and 1 more. Started Feb 2023; status: terminated.
02
Drugs
AMG 794
03
Conditions
non-small cell lung cancer (NSCLC)epithelial ovarian cancer (EOC)testicular germ cell cancer (TGCC)endometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05317078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317078.